Benzinga | Jan 19, 2021 09:03AM EST

Hillrom Announces Planned Acquisition Of Bardy Diagnostics, Inc. For Cash Consideration Of $375M

CHICAGO, Jan. 19, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced it has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx), an innovator in digital health and a leading provider of ambulatory cardiac monitoring technologies. Under the terms of the agreement, Hillrom will purchase BardyDx for a cash consideration of $375 million and future potential payments based on the achievement of certain commercial milestones. Hillrom is also acquiring net operating losses valued at more than $20 million that are expected to result in future tax benefits.